moneyheap
SNN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Smith & Nephew plc (SNN) stock moving?
Smith & Nephew's Q3 2026 trading update on Nov 4 showed revenue of $1,551M, up 3.4% on both underlying and reported bases, with double-digit growth in Sports Medicine Joint Repair and several product lines, and Orthopaedics back to growth. However, management cut full-year guidance to about 3% underlying revenue growth, about 4% trading profit growth (around $1,250M) and about $750M free cash flow, citing weak US Hips and Knees and market conditions. The company also confirmed that merger talks with J&J's orthopaedics unit had ended and that it is still exploring strategic options for Orthopaedics. The $500M buyback is on track, with $250M completed by the end of Q3. Price action: the stock closed at $32.46 on Nov 4 on volume of 2.68M shares, versus about 1.6M in the prior sessions, then hit a $33.00 intraday high on Nov 5 with 2.82M shares. It has since faded to $30.92 on Nov 10, roughly where it traded before the update (about $30.2 on Nov 3 and $30.88 on Oct 22). Analyst reaction is mixed: UBS raised its target but kept a Neutral rating, while Citigroup cut its target and kept a Buy rating. The main open question is the outcome of the Orthopaedics strategic review, which is not yet resolved.
News behind the analysis
- Smith+Nephew Q3 Revenue Rises 3.4% YoY To $1.551B; $250M Of $500M Buyback Completed; Confirms Johnson & Johnson Talks Ended, Still Exploring Orthopaedics Strategic OptionsQ3 revenue rose 3.4% to $1.551B, with Sports Medicine and ENT leading. The company confirmed the J&J orthopaedics talks ended and is still exploring strategic options for Orthopaedics.
- Smith & Nephew Ends Merger Talks with Johnson & Johnson's Orthopedics Unit and Cuts 2026 OutlookSmith & Nephew confirmed the end of merger discussions with J&J's orthopedics division and lowered its full-year 2026 revenue and profit guidance.
- UBS Adjusts Price Target for Smith & NephewUBS raised its price target on Smith & Nephew while keeping a Neutral rating.
- Citigroup Adjusts Price Target for Smith & NephewCitigroup lowered its price target on Smith & Nephew while maintaining a Buy rating.
- Smith & Nephew Implants Integrated into HipInsight SystemSurgical Planning Associates expanded its HipInsight System to include additional femoral and acetabular implant systems from Smith & Nephew.
- Smith & Nephew Reports Total Issued Share CapitalAs of October 31, 2026, the company had 837,434,165 voting shares outstanding, excluding 40,315,859 held in treasury.
About Smith & Nephew plc
Smith & Nephew is a UK-based global medical technology company listed in London (SN), with ADRs on the NYSE (SNN). It makes hip and knee implants, trauma and shoulder products, sports medicine tools for arthroscopic joint repair, and advanced wound care products, and had roughly $6.2 billion in sales in 2025.
How it makes money
It sells medical devices and consumables to hospitals, outpatient surgery centers and clinicians in three main businesses. Orthopaedics (hip, knee, trauma and extremities implants plus surgical robotics) is roughly 40% of sales. Sports Medicine & ENT (joint repair, arthroscopy tools and ENT devices) is roughly 30%. Advanced Wound Management (dressings, bioactive products and negative-pressure devices) is roughly 30%. These shares are approximate. The US is its largest market. In November 2026 the company cut its full-year 2026 guidance to about 3% underlying revenue growth and about $1.25 billion in trading profit. It is also running a $500 million share buyback.
What usually moves SNN
- Volumes of elective hip and knee surgery
- Product launches and competitiveness in US knee implants
- Execution of its RISE turnaround and margin plan
- Reimbursement in wound biologics and pricing pressure in China
- Moves between the US dollar and pound sterling